指南与共识

ACP 2026 门诊超重/肥胖非妊娠成人药物治疗联合生活方式调整临床指南

Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026)
RSS 订阅 · 指南共识 · 呼吸支持与睡眠 · 2026-06-15

美国内科医师学会(ACP)基于系统评价与 GRADE 方法制定本指南。对肥胖(BMI≥30 kg/m²)成人,建议在生活方式干预基础上启动药物治疗,一线为司美格鲁肽或替尔泊肽(中等确定性证据)。对超重(BMI 27–30 kg/m²)合并 2 型糖尿病、血脂异常、高血压、阻塞性睡眠呼吸暂停或心血管病者,亦建议药物治疗联合生活方式,一线为司美格鲁肽或替尔泊肽。

要点

  • 肥胖成人一线可选司美格鲁肽或替尔泊肽,均为中等确定性证据。
  • 超重合并 2 型糖尿病、血脂异常、高血压、OSA 或心血管病者一线亦为司美格鲁肽或替尔泊肽。
  • 启用或换药前须讨论获益、风险、费用、可及性、合并症与禁忌证。

核心结论

  • ACP 建议非妊娠超重或肥胖成人在门诊以生活方式调整联合药物治疗进行体重管理,均为条件性推荐。

研究设计与样本

  • ACP 制定的临床指南,基于超重或肥胖成人药物治疗的系统评价,采用 GRADE 方法。

主要发现

  • 肥胖(BMI≥30 kg/m²)成人一线为司美格鲁肽、替尔泊肽(中等确定性),二线芬特明-托吡酯(低确定性),三线利拉鲁肽(低确定性),四线纳曲酮-安非他酮(低确定性)。
  • 超重(BMI≥27 至 30 kg/m²)合并 2 型糖尿病、血脂异常、高血压、阻塞性睡眠呼吸暂停或心血管病者,一线为司美格鲁肽、替尔泊肽(中等确定性),二线为利拉鲁肽(低确定性)。

关键数值与推荐

  • 肥胖定义为 BMI≥30 kg/m²;超重定义为 BMI≥27 至 30 kg/m²。
  • 芬特明-托吡酯需每月妊娠检测,心血管疾病患者禁用;纳曲酮-安非他酮与自杀意念相关。

临床怎么用

  • 门诊对符合 BMI 及合并症条件的非妊娠成人,可在生活方式调整基础上启动推荐药物,并按线级选择。
  • 启药或换药前与患者共同讨论获益、风险、费用、可及性、合并症、减重目标、预期寿命、价值观偏好及禁忌证与警告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ann Intern Med. 2026 Aug;179(8):1177-1185. doi: 10.7326/ANNALS-25-02714. Epub 2026 Jun 16. ABSTRACT DESCRIPTION: The American College of Physicians (ACP) developed this clinical guideline for internal medicine physicians and other clinicians caring in outpatient settings for adults with overweight or obesity. METHODS: This guideline is based on systematic reviews of pharmacologic treatments in adults with overweight or obesity and used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. RECOMMENDATION 1: ACP suggests initiating one of the following pharmacologic treatments with lifestyle modifications for weight management in nonpregnant adults with obesity (body mass index ≥30 kg/m 2 ) in outpatient settings (conditional recommendation): First-line treatments are semaglutide (moderate-certainty evidence) and tirzepatide (moderate-certainty evidence); second-line treatment is phentermine-topiramate (low-certainty evidence); third-line treatment is liraglutide (low-certainty evidence); fourth-line treatment is naltrexone-bupropion (low-certainty evidence). When initiating a recommended medication for weight management or switching to another recommended medication because of an inadequate response, clinicians and patients should discuss benefits, harms, costs, access and availability, clinical comorbidities, weight loss goals, life expectancy, values and preferences, and contraindications and warnings (for example, the requirement for monthly pregnancy tests with use of phentermine-topiramate, the contraindication to phentermine-topiramate in those with cardiovascular disease, and suicidal ideation with naltrexone-bupropion). RECOMMENDATION 2: ACP suggests initiating one of the following pharmacologic treatments with lifestyle modifications for weight management in nonpregnant adults with overweight (body mass index ≥27 to 30 kg/m 2 ) and type 2 diabetes, dyslipidemia, hypertension, obstructive sleep apnea, or cardiovascular disease (conditional recommendation): First-line treatments are semaglutide (moderate-certainty evidence) and tirzepatide (moderate-certainty evidence); second-line treatment is liraglutide (low-certainty evidence). When initiating a recommended medication for weight management or switching to another recommended medication because of an inadequate response, clinicians and patients should discuss benefits, harms, costs, access and availability, clinical comorbidities, weight loss goals, life expectanc

来源:指南共识 · 呼吸支持与睡眠,查看原文。版权归原作者所有。

引用

  1. 指南共识 · 呼吸支持与睡眠:Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026)

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。